Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VDJ001 in Moderate-to-severe Active Rheumatoid Arthritis
NCT06726096Phase 3Enrolling by invitation
- Sponsor
- Beijing VDJBio Co., Ltd.
- Start
- Apr 2025
- Primary completion
- Apr 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of VDJ-001 in rheumatoid arthritis (RA) (3 arms), sponsored by Beijing VDJBio Co., Ltd. Primary endpoint: American College of Rheumatology 50% Response at 24 weeks. Started Apr 2025; status: enrolling by invitation.
02
Drugs
VDJ-001
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT06726096.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726096.